

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification ⁷ : A61K 31/00	A2	(11) International Publication Number: WO 00/28980 (43) International Publication Date: 25 May 2000 (25.05.00)
(21) International Application Number: PCT/US99/26655		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 10 November 1999 (10.11.99)		
(30) Priority Data: 60/108,370 13 November 1998 (13.11.98) US		
(71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).		
(72) Inventors; and		
(75) Inventors/Applicants (for US only): IYENGAR, Smriti [IN/US]; 1507 Redwood Drive, Carmel, IN 46032 (US). JONES, Carrie, Kimberly [US/US]; 221 East Michigan, Apartment 605, Indianapolis, IN 46204 (US). SHANNON, Harlan, Edgar [US/US]; 4229 Rolling Springs Drive, Carmel, IN 46033 (US).		Published <i>Without international search report and to be republished upon receipt of that report.</i>
(74) Agents: HARVEY, Suzanne, M. et al.; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).		

(54) Title: METHOD FOR TREATING PAIN

(57) Abstract

The present invention provides a method for treating pain comprising administering to a mammal an analgesic composition comprising duloxetine and one or more NSAIDs.

Isobogram of the Interaction Between Duloxetine and Ibuprofen on Writhing in Mice



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD FOR TREATING PAIN

For many types of pain, the method for treating the pain is through administration of aspirin or any of a number of non-steroidal antiinflammatory agents, NSAIDs. Frequently, the administration of the NSAID provides the relief sought. However, if the relief of pain is insufficient with NSAIDs alone, these agents may be combined with orally effective morphine-like agents, such as codeine and other opioids. Because these two agents exert their effects by different mechanisms, combinations of these two classes of drugs usually can achieve an analgesic effect that would otherwise require a higher dose of opioid, but with fewer side effects. Nonetheless, even at a lesser dose of opioid, resulting in fewer side effects, it has been well documented that any dose of an opioid has the potential for severe side effects. For example, morphine and its related opioids may cause respiratory depression, nausea, vomiting, dizziness, mental clouding, dysphoria, pruritus, constipation, increased pressure in the biliary tract, urinary retention, hypotension, tolerance, and physical dependence. (*The Pharmacological Basis of Therapeutics*, 9th edition, Macmillan Publishing Co., 1996, pp 533-540.)

New safer and effective methods for the treatment of pain are in constant demand. The discovery of other agents which provide an analgesic synergism in combination with NSAIDs but have a reduction in the severity of the side effects profile are in constant demand. Such a combination is the subject of the present invention.

The present invention addresses a long felt need for a safe and effective treatment for pain.

The present invention provides a method for treating pain in a mammal requiring said treatment, which comprises administering to said mammal an effective amount

of duloxetine or a pharmaceutically acceptable salt or solvate thereof; in combination with an effective amount of one or more NSAIDs.

The present invention also provides the use of
5 duloxetine or a pharmaceutically acceptable salt or solvate thereof in combination with one or more NSAIDs for the manufacture of a medicament for treating pain.

Furthermore, the present invention provides the use of duloxetine or a pharmaceutically acceptable salt or solvate thereof in combination with one or more NSAIDs for
10 treating persistent pain.


According to yet another aspect, the present invention provides a pharmaceutical formulation comprising a combination of duloxetine, or a pharmaceutically acceptable
15 salt or solvate thereof, one or more NSAIDs, and a pharmaceutical carrier, diluent or excipient.

Fig. 1 is an Isobogram of the interaction between duloxetine and ibuprofen on writhing in mice.

Fig. 2 is an Isobogram of the interaction
20 between duloxetine and ibuprofen on hyperalgesia in rats.

The present invention provides a method for treating pain in a mammal requiring said treatment, which comprises administering to said mammal an effective amount of duloxetine or a pharmaceutically acceptable salt or
25 solvate thereof; in combination with an effective amount of one or more NSAIDs.

Duloxetine, the (+)-enantiomer of N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine, is usually administered as the hydrochloride salt. Duloxetine is
30 represented in formula I:



Duloxetine and its pharmaceutically acceptable salts and solvates were first taught by U.S. Patent No. 4,956,388, the teachings of which are herein 5 incorporated by reference in their entirety. The term "duloxetine" shall refer to any acid addition salt and the free base of the molecule.

In the method according to the invention, the term "combination" shall refer to the administration of 10 duloxetine, or a pharmaceutically acceptable salt or solvate thereof; and one or more NSAIDs. The administration of the compounds may be in any order, or may be concurrent. For example, a mammal may be given the NSAIDs first, then given the duloxetine, or given the duloxetine first, then given 15 the NSAIDs. Furthermore, the mammal may be given both, the duloxetine and the NSAIDs, concurrently.

In the method according to the invention, the term "treating" and "treatment" include prophylaxis or prevention of pain, amelioration or elimination of the developed pain 20 once it has been established, or alleviation of the characteristic symptoms of such pain.

The skilled artisan will appreciate that pain is a heterogeneous disorder. In the method according to the invention, the term "pain" shall refer to all types of pain, 25 including acute and persistent pain. Preferably, the term

-4-

shall refer to persistent pains, such as, but not limited to, neuropathic pain, diabetic neuropathy, fibromyalgia, pain associated with somatoform disorders, arthritic pain, cancer pain, neck pain, shoulder pain, back pain, cluster 5 headaches, tension-type headache, migraine, herpes neuralgia, phantom limb pain, central pain, dental pain, NSAID-resistant pain, visceral pain, surgical pain, post-operative pain, bone injury pain, pain during labor and delivery, pain resulting from burns, including sunburn, 10 post-partum pain, angina pain, and genitourinary tract-related pain including cystitis. The term persistent pain shall also preferably refer to nociceptive pain or nociception.

The term "NSAID", as used herein, represents a 15 nonsteroidal anti-inflammatory agent which can be identified as such by the skilled artisan. NSAIDs are known for their inhibition of cyclooxygenases I and II, the enzymes responsible for the biosynthesis of the prostaglandins and certain related autacoids. NSAIDs are known to be 20 antipyretic, analgesic, and antiinflammatory. The term NSAID shall, in addition, refer to any compound acting as a non-steroidal antiinflammatory agent. For example, *The Pharmacological Basis of Therapeutics*, 9th edition, Macmillan Publishing Co., 1996, pp 617-655, provides well 25 known examples of NSAIDs. The term includes, but is not limited to, salicylic acid derivatives, such as salicylic acid, aspirin, methyl salicylate, diflunisal, salsalate, olsalazine, and sulfasalazine; para-aminophenol derivatives, such as acetaminophen; sulindac; etodolac; tolmetin; 30 ketorolac; diclofenac; propionic acid derivatives, such as ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen, and oxaprozin; acetic acid derivatives, such as indomethacin; enolic acids, such as piroxicam; and cyclooxygenase II inhibitors, such as celecoxib, and

-5-

rofecoxib. Applicants appreciate that new NSAIDs may be in development, and the present invention contemplates a synergistic combination and compositions comprising such new agents with duloxetine as well.

5 Preferably, the NSAID is selected from aspirin, ibuprofen, naproxen, celecoxib and rofecoxib.

Ibuprofen, celecoxib, and rofecoxib are particularly preferred NSAIDs in the method according to the invention.

10 According to a preferred aspect, the present invention provides a method for the treatment of pain in a mammal requiring said treatment, which comprises administering to said mammal an effective amount of ibuprofen, celecoxib, or rofecoxib and an effective amount
15 of duloxetine or a pharmaceutically acceptable salt or solvate thereof.

According to a more preferred aspect, the present invention provides a method for the treatment of persistent pain in a mammal requiring said treatment, which comprises
20 administering to said mammal an effective amount of ibuprofen, celecoxib, or rofecoxib and an effective amount of duloxetine or a pharmaceutically acceptable salt or solvate thereof.

In the methods according to the invention the
25 mammal may be any animal in the Mammalian Class of higher vertebrates, for example a rodent, dog, cat, primate or human. Preferably the mammal is a human.

The effective amounts or dosages of NSAIDs and duloxetine administered will, of course, vary depending on
30 known factors such as the pharmacodynamic characteristics of the particular agent, and its mode and route of administration; age, health, and weight of the recipient; nature and extent of the symptoms, kind of concurrent treatment, frequency of treatment, and the effect desired.

- 6 -

Duloxetine is effective over a wide dosage range; however, it is desirable to administer a dosage that is as low as possible. Usually, the daily dosage can be such that the active ingredient is administered at a daily dosage of from 5 about 0.2 mg to about 200 mg duloxetine and from about 0.6 to about 200 mg/kg of NSAIDs.

The amount of NSAIDs present in combination with duloxetine is adjusted in ratio to the duloxetine dosage. However, it will be understood that the amount of the 10 compound actually administered will be determined by a physician in light of the relevant circumstances including the condition to be treated, the choice of compound to be administered, the age, weight, and response symptoms, and the chosen route of administration. Therefore the dosage 15 ranges are not intended as a limitation to the scope of the invention.

The combination of duloxetine, or a pharmaceutically acceptable salt or solvate thereof, and one or more NSAIDs may be administered in a weight ratio of 20 duloxetine to NSAIDs of from about 1 to about 100. As stated, the NSAIDs may be administered first, and then the duloxetine; duloxetine may be administered first, and then the NSAIDs; or they may both be administered concurrently.

A preferred combination is a weight ratio of 25 duloxetine to NSAIDs of from about 1 to about 30. A further preferred ratio is from about 1 to about 10. A final preferred ratio is from about 1 to about 3.

While duloxetine and NSAIDs are preferably administered orally to mammals susceptible to or suffering 30 from pain, they may also be administered by a variety of other routes such as the transdermal, parenteral, epidural, subcutaneous, intranasal, intramuscular and intravenous routes. Such formulations may be designed to provide delayed or controlled release using formulation techniques

-7-

which are known in the art. It will substantially always be preferred, however, to administer both duloxetine and the NSAIDs as tablets or capsules and such pharmaceutical forms are recommended.

5 The materials for the present invention can be purchased or prepared by a variety of procedures well known to those of ordinary skill in the art. Duloxetine can be prepared as described by U.S. Patent No. 4,956,388, previously incorporated by reference.

10 A preferred duloxetine enteric formulation is a pellet formulation comprising a) a core consisting of duloxetine and a pharmaceutically acceptable excipient; b) an optional separating layer; c) an enteric layer comprising hydroxypropylmethylcellulose acetate succinate
15 (HPMCAS) and a pharmaceutically acceptable excipient; d) an optional finishing layer; as is described in U.S. Patent No. 5,508,276, the teachings of which are herein incorporated by reference. The following formulation example demonstrates the preparation of such a preferred
20 formulation.

Formulation Example

10 mg Duloxetine base/capsule

Bill of Materials

25 Beads

Sucrose - starch nonpareils,

20-25 mesh 60.28 mg

Duloxetine layer

11-21

30 Hydroxypropylmethylcellulose 3-34

Separating layers

11.21

Spreading layer

Hydroxypropylmethylcellulose 2.51

SUCROSE 5.00

Talc, 500 mesh 10.03

- 8 -

Enteric layer

	HPMCAS, LF grade, Shin-Etsu	
	Chemical Co., Tokyo Japan	25.05
	Triethyl citrate	5.00
5	Talc, 500 mesh	7.52
	Finishing layer	
	Hydroxypropylmethylcellulose	8.44
	Titanium dioxide	2.81
	Talc	<u>Trace</u>
10		141.60 mg

The duloxetine layer was built up by suspending duloxetine in a 4% w/w solution of the Hydroxypropylmethylcellulose in water, and milling the suspension with a CoBall 15 Mill (Fryma Mashinen AG, Rheinfelden, Switzerland) model MS-12. A fluid bed dryer with a Wurster column was used to make this product, at a batch size of 1.0 kg. The separating layer was added from a 4% w/w solution of the Hydroxypropylmethylcellulose in water, in which the sucrose 20 was also dissolved.

In order to prepare the enteric coating suspension, purified water was cooled to 10 °C and the polysorbate, triethyl citrate and silicone emulsion were added and dispersed or dissolved. Then the HPMCAS and talc 25 were added and agitated until homogeneity was obtained, and the HPMCAS was fully neutralized by addition of ammonium hydroxide until solution of the polymer was complete. To this suspension, a carboxymethylcellulose aqueous solution, 0.5% w/w, was added and blended thoroughly. The enteric 30 suspension was maintained at 20 °C during the coating process. The enteric suspension was then added to the partially completed pellets in the Wurster column at a spray rate of about 15 mL/min, holding the temperature of the

-9-

inlet air at about 50 °C. The product was dried in the Wurster at 50 °C when the enteric suspension had been fully added, and then dried on trays for 3 hours in a dry house at 60 °C. A finishing layer was then applied which consisted
5 of a 4.5% w/w Hydroxypropylmethylcellulose solution containing titanium dioxide and propylene glycol as plasticizer. The pellets were completely dried in the fluid bed dryer and then were filled in size 3 gelatin capsules.

Compositions suitable for internal administration
10 contain from about one half (0.5) milligrams to about 600 milligrams of duloxetine or NSAID per unit. In these pharmaceutical compositions, duloxetine or NSAID will ordinarily be present in an amount of from about 0.5% to about 95% by weight based on the total weight of the
15 composition.

Typical compositions include duloxetine or a pharmaceutically acceptable salt or solvate thereof and one or more NSAIDs, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or
20 be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active compound
25 will usually be mixed with a carrier which may be in the form of an ampoule, capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound. The
30 active compound can be adsorbed on a granular solid container for example in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil,

-10-

gelatine, lactose, amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone. The formulations may also include
5 wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, or flavoring agents. The formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing
10 procedures well known in the art. The skilled artisan will appreciate that the compositions of duloxetine or one or more NSAIDs, as described prior, may also contain both duloxetine and one or more NSAIDs, in the same ratios as described for separate compositions.

15 The pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compounds.

20 For parental application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.

25 Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.

30 Generally, duloxetine is dispensed in unit form comprising from about 1 mg to about 200 mg in a pharmaceutically acceptable carrier per unit dosage.

Most preferably, the solid oral formulation of duloxetine or of duloxetine and one or more NSAIDs is

-11-

- contained in packaging materials which protect the formulation from moisture and light. For example, suitable packaging materials include amber colored high density polyethylene bottles, amber colored glass bottles, and other
- 5 containers made of a material which inhibits the passage of light. Most preferably, the packaging will include a desiccant pack. The container may be sealed with an aluminum foil blister to provide the desired protection and maintain product stability.
- 10 The following typical formulae are provided for the interest and information of the pharmaceutical scientist.

-12-

Formulation 1

Hard gelatin capsules are prepared using the following ingredients:

	Quantity <u>(mg/capsule)</u>
	5
	(+)-Duloxetine, hydrochloride
	Ibuprofen
10	Starch, dried
	Magnesium stearate
	Total
	20 mg
	20
	150
	<u>10</u>
	200 mg

Formulation 2

15 A tablet is prepared using the ingredients below:

	Quantity <u>(mg/capsule)</u>
20	(+)-Duloxetine, hydrochloride
	Ibuprofen
	Cellulose, microcrystalline
	Silicon dioxide, fumed
	Stearic acid
25	Total
	10
	10
	275
	10
	<u>5</u>
	310 mg

The components are blended and compressed to form tablets each weighing 310 mg.

-13-

Formulation 3

An aerosol solution is prepared containing the following components:

	<u>Weight</u>
5	
Ibuprofen	10 mg
(+)-Duloxetine, hydrochloride	5
Ethanol	25.75
Propellant 22	
10 (Chlorodifluoromethane)	<u>60.00</u>
Total	100.75 mg

The active compound is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to - 15 30°C and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remainder of the propellant. The valve units are then fitted to the container.

20

Formulation 4

Tablets, each containing 80 mg of active ingredient, are made as follows:

25	Ibuprofen	60 mg
	(+)-Duloxetine, hydrochloride	20 mg
	Starch	30 mg
	Microcrystalline cellulose	20 mg
	Polyvinylpyrrolidone (as 10% solution in water)	4 mg
30	Sodium carboxymethyl starch	4.5 mg
	Magnesium stearate	0.5 mg
	Talc	<u>1 mg</u>
	Total	140 mg

-14-

The active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The aqueous solution containing polyvinyl-pyrrolidone is mixed with the resultant powder, and the
5 mixture then is passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50°C and passed through a No. 18 mesh U.S. Sieve. The sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the
10 granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 170 mg.

The following Examples are provided to better elucidate the practice of the present invention and should not be interpreted in any way as to limit the scope of the
15 same.

Utility Test Methods

The unexpectedly enhanced analgesic activity of the composition of the invention was evidenced by tests initially conducted on mice. Mice weighing from about 18-30
20 grams at the time of testing were used for the following study. All mice were dosed by the oral route with vehicle, a dose of duloxetine, a dose of an NSAID, or a dose consisting of the combination of duloxetine and an NSAID. A stock suspension of NSAID was prepared in 5% acacia. All
25 dosing suspensions were prepared by dilution of the stock suspension with distilled water.

Mouse Writhing Test

An accepted procedure for detecting and comparing the analgesic activity of different classes of analgesic
30 drugs for which there is a good correlation with human analgesic activity is the prevention of acetic acid-induced writhing in mice. Mice are orally administered various doses of duloxetine in combination with ibuprofen, duloxetine alone, ibuprofen alone, and placebo prior to

-15-

testing. The mice are then injected intraperitoneally with acetic acid (0.55% solution, 10 mL/kg) five minutes prior to a designated observation period. For scoring purposes "writhe" is indicated by whole body stretching or
5 contracting of the abdomen during an observation period beginning about five minutes after receiving the acetic acid. Inhibition of writhing behavior is demonstrative of analgesic activity. Haubrich et al., "Pharmacology of pravadolone: a new analgesic agent", *The Journal of Pharmacology and Experimental Therapeutics*, 255 (1990)
10 511-522.

Doses of duloxetine in combination with ibuprofen were administered in a fixed-dose ratio of 1 part duloxetine and 10 parts ibuprofen. Duloxetine alone was dosed at 1.0,
15 3.0, 10 and 30 mg/kg. Ibuprofen alone was dosed at 10, 30, 100 and 300 mg/kg. Actual total doses of the combination of duloxetine and ibuprofen were 3, 10, 30 and 100 mg/kg.

All ED50 values and their standard error of means (SEM) were determined using accepted numerical methods. For
20 example, see R.E. Kirk (1982) "Experimental Design: Procedures for the behavioral sciences," 2nd ed. The interaction of the dosages on acetic acid-induced writhing in mice is demonstrated by the Loewe isobogram (S. Loewe, *Pharm. Rev.* 9, 237-242 (1957)).

25 The synergistic activity of a ratio of 1:10 duloxetine to ibuprofen on acetic acid-induced writhing in mice is demonstrated by the data in the Loewe isobogram in Fig. 1. In the isobographic figure, the analgesic effects of duloxetine, referred to as the ED50 dosages, are presented on the X-axis and of ibuprofen on the Y-axis. The solid line connecting the ED50 dosages of duloxetine (alone) and NSAID (alone) represents the "ED50 addition line" which indicates the expected location of the ED50's for duloxetine

-16-

and NSAID combinations if simple additivity were to describe their combined effects.

According to Loewe's isobolic theory, if the analgesic effects are simply additive to one another, then
5 the expected location of the ED50's of duloxetine and NSAID component of each fixed dosage ratio would lie on the ED50 addition line. Combination ED50 values located significantly below the ED50 addition line would represent an unexpected synergistic effect of concomitant
10 administration of duloxetine and ibuprofen and combination ED50 values located above the line would represent unexpected diminished analgesic effect. The open symbol represents the effects of duloxetine and ibuprofen administered in a fixed-dose ratio of 1 part duloxetine and
15 10 parts ibuprofen.

One method to establish the significance of such unexpected enhanced or diminished activity is to calculate the SEM values for each ED50. If the SEM values do not overlap the line of addition, then the ED50 values are
20 significantly different from the line of addition.

The data presented in Fig. 1 show that administration of both duloxetine and ibuprofen show a statistically significant synergistic effect, since the dose combination ED50 value falls below the line of addition and
25 neither the vertical nor horizontal SEMs overlap the line of addition.

Carrageenan-induced Thermal Hyperalgesia in Rats

Another accepted method for detecting and comparing the analgesic activity of different classes of
30 analgesic compounds for which there is good correlation with human analgesic activity is the reversal of carrageenan-induced thermal hyperalgesia in rats (Hargreaves et al. *Pain* 32:77-88, 1988).

-17-

Rats were administered a dose of duloxetine, ibuprofen, duloxetine:ibuprofen in combination, or vehicle and then injected subcutaneously into one hindpaw with carrageenan (1.5% w/v, 100 μ l). The response to a noxious thermal stimulus was determined two hours later using a commercially available thermal plantar device (Ugo Basil, Italy) according to established methods (Hargreaves et al. *Pain* 32:77-88, 1988). Briefly, animals were habituated to a plastic behavioral enclosure for 5 min. A heat source was positioned directly beneath a hindpaw and the time taken for hindpaw withdrawal monitored automatically. If the animal did not respond within 20 sec, the stimulus was automatically terminated to prevent tissue damage. Measurements for both the injured and contralateral (control) hindpaw were recorded. Thermal hyperalgesia is evidenced by a shorter response latency by the injured as compared to the control paw.

Duloxetine alone was administered at doses of 1.0, 3.0, 10 and 30 mg/kg. Ibuprofen alone was administered at doses of 10, 30, 100 and 300 mg/kg. Doses of duloxetine in combination with ibuprofen were administered in a fixed-dose ratio of 1 part duloxetine and 10 parts ibuprofen. Actual total doses of the combination were 1, 3, 10, 30, and 100 mg/kg.

All ED₅₀ values and their standard error of means (SEM) were determined using accepted numerical methods. For example, see R.E. Kirk (1982) "Experimental Design: Procedures for the behavioral sciences," 2nd ed. The interaction of the dosages on carrageenan-induced thermal hyperalgesia in rats is demonstrated by the Loewe isobologram (S. Loewe, *Pharm. Rev.* 9, 237-242 (1957)).

The interaction of duloxetine and ibuprofen on carrageenan-induced thermal hyperalgesia in rats is demonstrated by the data in the Loewe isobologram in Fig. 2.

-18-

In the isobolographic figure, the analgesic effects of duloxetine, referred to as ED50 dosages, are presented on the X-axis and of ibuprofen on the Y-axis. As above, the line connecting the ED50 dosages of duloxetine alone and 5 ibuprofen alone represents the "ED50 addition line" which indicates the expected location of the ED50 values for duloxetine and ibuprofen combinations if simple additivity were to describe their combined effects. Combination ED50 values located significantly below the ED50 addition line 10 would represent an unexpected synergistic effect of concomitant administration of duloxetine and ibuprofen and combination ED50 values located above the line would represent unexpected diminished analgesic effect. The open symbol represents the effects of duloxetine and ibuprofen 15 administered in a fixed-dose ratio of 1 part duloxetine and 10 parts ibuprofen.

Data presented in Fig. 2 show that administration of both duloxetine and ibuprofen show a statistically significant synergistic effect, since the dose combination 20 ED50 value falls below the line of addition and neither the vertical nor horizontal SEMs overlap the line of addition.

WE CLAIM:

1. The use of duloxetine or a pharmaceutically acceptable salt or solvate thereof in combination with one
5 or more NSAIDs for the manufacture of a medicament for treating pain.
2. The use of Claim 1 wherein the NSAID is selected from the group consisting of salicylic acid, aspirin, methyl salicylate, diflunisal, salsalate, olsalazine,
10 sulfasalazine, acetaminophen, indomethacin, sulindac, etodolac, tolmetin, ketorolac, diclofenac, ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin, piroxicam, celecoxib, and rofecoxib.
3. The use of Claim 2 wherein the NSAID is selected
15 from the group consisting of aspirin, ibuprofen, naproxen, celecoxib, and rofecoxib.
4. The use of Claim 3 wherein the NSAID is selected from the group consisting of ibuprofen, celecoxib, and rofecoxib.
- 20 5. The use of any of Claims 1 through 4 wherein the pain is persistent pain.
6. The use of Claim 5 wherein the persistent pain is selected from the group consisting of neuropathic pain, diabetic neuropathy, fibromyalgia, pain associated with
25 somatoform disorders, arthritic pain, cancer pain, neck pain, shoulder pain, back pain, cluster headaches, tension-type headache, migraine, herpes neuralgia, phantom limb pain, central pain, dental pain, NSAID-resistant pain, visceral pain, surgical pain, post-operative pain, bone

-20-

injury pain, pain during labor and delivery, pain resulting from burns, post-partum pain, angina pain, genitourinary tract-related pain, and nociceptive pain.

7. The use of duloxetine or a pharmaceutically acceptable salt or solvate thereof in combination with one or more NSAIDs for treating pain.

8. A method for treating pain in a mammal requiring said treatment, which comprises administering to said mammal an effective amount of duloxetine or a pharmaceutically acceptable salt or solvate thereof; in combination with an effective amount of one or more NSAIDs.

9. The method of Claim 8 wherein the NSAID is selected from the group consisting of salicylic acid, aspirin, methyl salicylate, diflunisal, salsalate, olsalazine, sulfasalazine, acetaminophen, indomethacin, sulindac, etodolac, tolmetin, ketorolac, diclofenac, ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin, piroxicam, celecoxib, and rofecoxib.

10. The method of Claim 9 wherein the NSAID is selected from the group consisting of aspirin, ibuprofen, naproxen, celecoxib, and rofecoxib.

11. The method of Claim 10 wherein the NSAID is selected from the group consisting of ibuprofen, celecoxib, and rofecoxib.

25 12. The method of any of Claims 8 through 11 wherein the pain is persistent pain.

13. The method of Claim 12 wherein the persistent pain is selected from the group consisting of neuropathic pain, diabetic neuropathy, fibromyalgia, pain associated with somatoform disorders, arthritic pain, cancer pain, neck
5 pain, shoulder pain, back pain, cluster headaches, tension-type headache, migraine, herpes neuralgia, phantom limb pain, central pain, dental pain, NSAID-resistant pain, visceral pain, surgical pain, post-operative pain, bone injury pain, pain during labor and delivery, pain resulting
10 from burns, post-partum pain, angina pain, genitourinary tract-related pain, and nociceptive pain.

14. The method of any of Claims 8 through 11 wherein the effective amount of duloxetine and the NSAID is in a weight ratio of from about 1 to about 10.

15 15. The method of Claim 14 wherein the effective amount of duloxetine and the NSAID is in the weight ratio of from about 1 to about 3.

16. The method of any of Claims 8 through 15 wherein the mammal is human.

20 17. The method of any of Claims 8 through 16 wherein duloxetine is the hydrochloride salt.

18. A pharmaceutical formulation comprising duloxetine, or a pharmaceutically acceptable salt or solvate thereof, one or more NSAIDs, and a pharmaceutical carrier, diluent,
25 or excipient.

19. The formulation of Claim 18 wherein the NSAID is selected from the group consisting of salicylic acid, aspirin, methyl salicylate, diflunisal, salsalate,

-22-

olsalazine, sulfasalazine, acetaminophen, indomethacin, sulindac, etodolac, tolmetin, ketorolac, diclofenac, ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin, piroxicam, celecoxib, and rofecoxib.

5 20. The formulation of Claim 19 wherein the NSAID is selected from the group consisting of aspirin, ibuprofen, naproxen, celecoxib and rofecoxib.

21. The formulation of Claim 20 wherein the NSAID is ibuprofen, celecoxib, and rofecoxib.

10 22. The formulation of any of Claims 18 through 21 wherein duloxetine is the hydrochloride salt.




Fig. 1




Fig. 2



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification 7 : A61K 31/38, 31/19, A61P 29/00	A3	(11) International Publication Number: WO 00/28980 (43) International Publication Date: 25 May 2000 (25.05.00)
(21) International Application Number: PCT/US99/26655		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 10 November 1999 (10.11.99)		
(30) Priority Data: 60/108,370 13 November 1998 (13.11.98) US		
(71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).		
(72) Inventors; and		Published
(75) Inventors/Applicants (for US only): IYENGAR, Smriti [IN/US]; 1507 Redwood Drive, Carmel, IN 46032 (US). JONES, Carrie, Kimberly [US/US]; 221 East Michigan, Apartment 605, Indianapolis, IN 46204 (US). SHANNON, Harlan, Edgar [US/US]; 4229 Rolling Springs Drive, Carmel, IN 46033 (US).		With international search report.
(74) Agents: HARVEY, Suzanne, M. et al.; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).		(88) Date of publication of the international search report: 27 July 2000 (27.07.00)

(54) Title: COMBINATION OF DULOXETINE WITH NON-STEROIDAL ANTIINFLAMMATORY DRUG FOR TREATING PAIN

(57) Abstract

The present invention provides a method for treating pain comprising administering to a mammal an analgesic composition comprising duloxetine and one or more NSAIDs.

Isobologram of the Interaction Between Duloxetine and Ibuprofen on Writhing in Mice



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

INTERNATIONAL SEARCH REPORT

Inte. onal Application No
PCT/US 99/26655

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/38 A61K31/19 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	EP 0 908 186 A (LILLY CO ELI) 14 April 1999 (1999-04-14) claims 7-9,17 ---	1-22
Y	WO 97 35584 A (LILLY CO ELI) 2 October 1997 (1997-10-02) claims 1,2 ---	1-22
A	WO 98 46601 A (WHITESITT CELIA ANN ; LILLY CO ELI (US); SHANNON HARLAN EDGAR (US)) 22 October 1998 (1998-10-22) claims 14,26 ---	1-22
A	WO 98 46227 A (SAUERBERG PER ; LILLY CO ELI (US); MITCH CHARLES HOWARD (US); SHANNON HARLAN EDGAR (US)) 22 October 1998 (1998-10-22) claims 14,26 ---	1-22
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

28 April 2000

Date of mailing of the international search report

17/05/2000

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Gonzalez Ramon, N

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 99/26655

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>MILLAN M. J. ET AL: "WAY 100635 enhances both the antidepressant actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortex" EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 341, no. 2/3, 12 January 1998 (1998-01-12), pages 165-167, XP000904847 abstract see discussion</p> <p>---</p>	1-22
T	<p>PHARMACEUTICAL INFORMATION NETWORK: "Celecoxib linked to GI deaths in five patients" PNN PHARMACOTHERAPY LINE, 'Online! 20 April 1999 (1999-04-20), page 1 XP002136045 Retrieved from the Internet: <URL:http://pharminfo.com/pubs/pnn/pnn38_4.html> 'retrieved on 2000-04-19! abstract</p> <p>-----</p>	1-22

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/26655

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: 1, 5-8, 12-18, 22 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
See FURTHER INFORMATION SHEET PCT/ISA/210

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1,5-8,12-18,22

Present claims 1,5-8,12-18,22 relate to a compound defined by reference to a desirable characteristic or property, namely "non-steroidal antiinflammatory drug"

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds specifically mentioned in the examples and the claims with due regard to the general idea underlying the present application

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/26655

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
EP 0908186	A 14-04-1999	AU 9035498 A			16-03-1999
		WO 9909980 A			04-03-1999
		US 5942530 A			24-08-1999
WO 9735584	A 02-10-1997	AU 2587297 A			17-10-1997
		CA 2250042 A			02-10-1997
		EP 0906104 A			07-04-1999
WO 9846601	A 22-10-1998	AU 7247898 A			11-11-1998
WO 9846227	A 22-10-1998	AU 6966998 A			11-11-1998